Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02477878 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02477878 · ClinicalTrials.gov record · last posted 2022-07-12

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

StatusActive, Not Recruiting
PhasePhase 1
Started2016-07
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The treatment consists of increasing doses of BPX-501 T cell infusions to achieve a clinical response. Rimiducid will be investigated for the treatment of aGvHD after BPX-501 T cell infusion to determine a dose that can mitigate GvHD and preserve the graft versus leukemia effect.

Amendment record 19 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 19 times since 2015-06-18; most recent amendment 2022-07-10. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2018-11-15
Status change Recruiting→Active, Not Recruitingv14
2016-10-13
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT02477878
Lead Sponsor Bellicum Pharmaceuticals
Conditions Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma, Hematologic Neoplasms
Enrollment 10 participants
Start Date 2016-07
Primary Completion 2020-01-14 (estimated)
Study Completion 2033-01 (estimated)
Updated on ClinicalTrials.gov 2022-07-12